Protara Therapeutics (TARA) Long-Term Debt Issuances (2020)

Protara Therapeutics (TARA) recorded quarterly Long-Term Debt Issuances of $1.9 million in Q1 2020.

Protara Therapeutics (TARA) Long-Term Debt Issuances (2020) Analysis & Trends

Protara Therapeutics' Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at $1.9 million for Q1 2020.

In Q1 2020, Long-Term Debt Issuances changed N/A year-over-year to $1.9 million; the TTM figure through Sep 2020 stood at $1.9 million (changed N/A YoY), while the FY2013 annual figure was $4.3 million, changed N/A from the prior year.
Long-Term Debt Issuances was $1.9 million for Q1 2020 at Protara Therapeutics.
In the past five years, Long-Term Debt Issuances ranged from a high of $1.9 million in Q1 2020 to a low of $1.9 million in Q1 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	2.73 Mn
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	-
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Protara Therapeutics	216.35 Mn	216.35 Mn	-	-

Historic Data

Download Data

Date	Value
Mar 31, 2020	1.87 Mn
Mar 31, 2020	1.87 Mn